REported Outcomes in COPD with Trixeo in Real worlD

Trial Identifier: D5980R00051
Sponsor: AstraZeneca
NCTID:: NCT05213611
Start Date: August 2022
Primary Completion Date: June 2024
Study Completion Date: June 2024
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United Kingdom Ashton-Under-Lyne, United Kingdom
United Kingdom Bath, United Kingdom
United Kingdom Belfast, United Kingdom
United Kingdom Birkenhead, United Kingdom
United Kingdom Bury St Edmunds, United Kingdom
United Kingdom Cambridge, United Kingdom
United Kingdom Carmarthen, United Kingdom
United Kingdom Cippenham, United Kingdom
United Kingdom Dewsbury, United Kingdom
United Kingdom Gillingham, United Kingdom
United Kingdom Gloucestershire, United Kingdom
United Kingdom Greenisland, United Kingdom
United Kingdom Hampshire, United Kingdom
United Kingdom Harlow, United Kingdom
United Kingdom Leeds, United Kingdom
United Kingdom Leicester, United Kingdom
United Kingdom Louth, United Kingdom
United Kingdom Macclesfield, United Kingdom
United Kingdom Manchester, United Kingdom
United Kingdom Mundesley, United Kingdom
United Kingdom North Shields, United Kingdom
United Kingdom Nuneaton, United Kingdom
United Kingdom Prenton, United Kingdom
United Kingdom Preston, United Kingdom
United Kingdom Redruth, United Kingdom
United Kingdom Rhyl, United Kingdom
United Kingdom Stafford, United Kingdom
United Kingdom Taunton, United Kingdom
United Kingdom Waterlooville, United Kingdom
United Kingdom Watford, United Kingdom
United Kingdom Westcliff on Sea, United Kingdom
United Kingdom Wirral, United Kingdom